نتایج جستجو برای: myelofibrosis

تعداد نتایج: 4073  

2005
Hans C. Hasselbalch Eva Lengfelder

Journal: :Blood 2011
Ayalew Tefferi

It is currently assumed that myelofibrosis (MF) originates from acquired mutations that target the hematopoietic stem cell and induce dysregulation of kinase signaling, clonal myeloproliferation, and abnormal cytokine expression. These pathogenetic processes are interdependent and also individually contributory to disease phenotype-bone marrow stromal changes, extramedullary hematopoiesis, inef...

Journal: :Haematologica 2014
Hajnalka Andrikovics Tunde Krahling Katalin Balassa Gabriella Halm Andras Bors Magdalena Koszarska Arpad Batai Janos Dolgos Judit Csomor Miklos Egyed Andrea Sipos Peter Remenyi Attila Tordai Tamas Masszi

Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing, high resolution melting and Sanger-sequencing was applied for the detection of three driver mutations (in Janus kinase 2, calreticulin and myelopr...

2015
Adam Stelling Brian A. Jonas Hooman H. Rashidi Mehrdad Abedi Mingyi Chen Huey-Jen Lin

Primary myelofibrosis (PMF), per WHO criteria, is a clonal myeloproliferative neoplasm that usually presents with a proliferation of granulocytic and megakaryocytic lineages with an associated fibrous deposition and extramedullary hematopoiesis. The bone marrow histologic findings of this disorder are typically characterized by the presence of myeloid metaplasia with an associated reactive fibr...

Journal: :The New England journal of medicine 2012
Srdan Verstovsek Ruben A Mesa Jason Gotlib Richard S Levy Vikas Gupta John F DiPersio John V Catalano Michael Deininger Carole Miller Richard T Silver Moshe Talpaz Elliott F Winton Jimmie H Harvey Murat O Arcasoy Elizabeth Hexner Roger M Lyons Ronald Paquette Azra Raza Kris Vaddi Susan Erickson-Viitanen Iphigenia L Koumenis William Sun Victor Sandor Hagop M Kantarjian

BACKGROUND Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. METHODS In this double-blind trial, we randomly assigned patients with intermediate-2 or high-risk myelofibrosis to twice-daily oral ruxolitinib (155 patients) or placebo (154 patients). The primary end point was the proportion of patients with a reduction in sple...

Journal: :JPMA. The Journal of the Pakistan Medical Association 1981
K Hassan

A case of chronic myelocytic leukemia is reported. He developed blastic crisis as well as myelofibrosis, simultaneously as a complication, after 1-1/2 years treatment with myeleran.

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید